These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30027343)

  • 1. [Detection of drug risks after approval : Methods development for the use of routine statutory health insurance data].
    Foraita R; Dijkstra L; Falkenberg F; Garling M; Linder R; Pflock R; Rizkallah MR; Schwaninger M; Wright MN; Pigeot I
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Sep; 61(9):1075-1081. PubMed ID: 30027343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacovigilance in Germany : It is about time].
    Douros A; Schaefer C; Kreutz R; Garbe E
    Internist (Berl); 2016 Jun; 57(6):616-23. PubMed ID: 27224991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Benefits of large healthcare databases for drug risk research].
    Garbe E; Pigeot I
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Aug; 58(8):829-837. PubMed ID: 26092163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recording and assessment of medication errors : Experience of the Drug Commission of the German Medical Association].
    Köberle U; Stammschulte T; Gundert-Remy U; Pitzer M; Bräutigam K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Sep; 61(9):1066-1074. PubMed ID: 30022236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
    Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
    Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F
    Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection.
    Plessis L; Gómez A; García N; Cereza G; Figueras A
    Eur J Clin Pharmacol; 2017 Jun; 73(6):751-758. PubMed ID: 28251276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP
    Montastruc F; Bagheri H; Lacroix I; Damase-Michel C; Chebane L; Rousseau V; Jouanjus E; Lapeyre-Mestre M; Durrieu G; Montastruc JL
    Drug Saf; 2018 May; 41(5):511-514. PubMed ID: 29270770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
    Krähenbühl S
    Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.